Copaxone glatiramer acetate: Phase IIIb data

The open-label, U.S. Phase IIIb GLACIER trial in 209 patients with RRMS showed that thrice-weekly 40 mg Copaxone led to a 50% reduction in the adjusted mean annualized rate of injection-related advers...